Xcopri (cenobamate)

Medicinal product
Xcopri (cenobamate)

Xcopri is an anticonvulsant medication used to treat partial-onset seizures in adults.


Xcopri should be taken as directed by a doctor.

Routes of Administration

Xcopri is taken orally.

The recommended starting dose of Xcopri is 12.5mg once daily, increasing to a maintenance dose of 100mg once daily over a period of 6 weeks.


Xcopri is available in 12.5mg, 25mg, 50mg, 100mg, and 200mg tablets.

Xcopri is taken orally with or without food.

Xcopri is available in tablet form.

Xcopri is indicated for the treatment of partial-onset seizures in adults.

Xcopri is contraindicated in patients with a history of hypersensitivity to cenobamate or any of the other ingredients in the formulation.


Each Xcopri tablet contains 12.5mg, 25mg, 50mg, 100mg, or 200mg of the active ingredient cenobamate. Other ingredients include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.


Xcopri is available in 12.5mg, 25mg, 50mg, 100mg, and 200mg tablets.

Storage conditions

Xcopri should be stored at room temperature, away from heat and moisture.

Sale terms

Xcopri is available only with a prescription.



Common side effects of Xcopri include dizziness, fatigue, headache, nausea, and tremor. Serious side effects may include suicidal thoughts or behavior, allergic reactions, and liver problems.

Xcopri may cause dizziness, so patients should avoid driving or operating heavy machinery until they know how the medication affects them.

Symptoms of overdose may include dizziness, confusion, and loss of consciousness.

Xcopri may interact with other antiepileptic drugs, as well as some medications used to treat depression and anxiety.

ATC Code

Expiry date

Price Range

Antiepileptic drugs

Other antiepileptics

Xcopri works by reducing the activity of certain nerve cells in the brain, which can help prevent seizures.

Xcopri is absorbed quickly and reaches its peak concentration in the blood within 1-4 hours after dosing. It is metabolized in the liver and excreted in the urine.

Clinical trials of Xcopri have shown it to be effective in reducing the frequency of partial-onset seizures in adults. In the clinical trials, Xcopri has been shown to be effective in reducing partial-onset seizures in adults. The trials included both double-blind, placebo-controlled studies and open-label extension studies.

The clinical trials for Xcopri included adult patients with partial-onset seizures, with or without secondary generalization, who were not adequately controlled with their current antiepileptic drugs.

In the clinical trials, Xcopri demonstrated a statistically significant reduction in partial-onset seizure frequency compared to placebo. The most common adverse reactions included dizziness, somnolence, and headache.